EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

A rare neurological adverse event of palbociclib: a chronic inflammatory demyelinating polyneuropathy (CIDP) mimic

Joy Zeynoun, Madeline Evans, Kimberly Boldig, Haythem Ali

Breast Cancer Research and Treatment · 2026-11 · 220 (1)

DOI: 10.1007/s10549-026-08081-6 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 04.11.2026. Verfasst von Joy Zeynoun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Henry Ford Health, Detroit, MI, USA. Hauptthemen laut MEDLINE: Pyridines, Breast Neoplasms, Piperazines, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) breast cancer accounts for approximately 65–70% of all breast cancer cases. First-line treatment for metastatic HR+/HER2– disease typically includes endocrine therapy combined with a CDK4/6 inhibitor, achieving progression-free survival (PFS) of 24–33 months with preserved quality of life. Although CDK4/6 inhibitors are generally well tolerated, they are associated with hematologic and gastrointestinal toxicities. We describe a patient who developed features of chronic immune-mediate polyradiculoneuropathy associated with neurofascin antibodies following initiation of palbociclib.

Methods

We conducted a detailed clinical review of a patient with metastatic HR+/HER2– breast cancer who developed progressive bilateral upper and lower extremity weakness after starting palbociclib. Clinical presentation, laboratory findings, imaging studies, electrodiagnostic testing, and treatment response were reviewed.

Results

A 43-year old female with metastatic HR+/HER2- breast cancer developed asymmetric progressive weakness and sensory symptoms approximately two weeks after initiating palbociclib. Electrodiagnostic testing demonstrated a mixed axonal and demyelinating sensorimotor polyneuropathy meeting EAN/PNS criteria for an acquired inflammatory demyelinating polyradiculoneuropathy. Initial diagnostic considerations included acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and multifocal CIDP (formerly termed multifocal acquired demyelinating sensory and motor neuropathy [MADSAM]). Despite initial improvement following treatment with IVIG, the patient experienced continued neurologic progression requiring plasmapheresis, repeat IVIG, high-dose corticosteroids, and rituximab. Subsequent testing demonstrated anti-neurofascin-155 and anti-neurofascin-186 antibody positivity. Longitudinal follow-up demonstrated significant functional recovery following rituximab therapy.

Conclusion

This case suggests a possible association between palbociclib exposure and the development of chronic immune-mediate polyradiculoneuropathy associated with neurofascin antibodies. Clinicians should consider immune mediated neuropathies in patients receiving CDK4/6 inhibitor therapy who develop weakness, sensory deficits, and areflexia. Further investigation is warranted to better characterize potential immunologic effects of CDK4/6 inhibition and their relationship to autoimmune neurologic disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridinesBreast NeoplasmsPiperazinesPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingAntineoplastic AgentsProtein Kinase InhibitorsHumansFemaleAdultDiagnosis, Differential

Stichwörter der Autor:innen

Breast CancerImmune mediated polyradiculoneuropathyPalbociclib

Substanzen

PyridinesPiperazinespalbociclibAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Neurology, Henry Ford Health, Detroit, MI, USA.
  • Wayne State University School of Medicine, Detroit, MI, USA.
  • Department of Hematology/Oncology, Henry Ford Health, Detroit, MI, USA.
  • Department of Hematology/Oncology, Henry Ford Health, Detroit, MI, USA. alihayth@msu.edu.
  • Michigan State University, East Lansing, MI, USA. alihayth@msu.edu.

Zitieren

APA

Zeynoun, J., Evans, M., Boldig, K., & Ali, H. (2026). A rare neurological adverse event of palbociclib: a chronic inflammatory demyelinating polyneuropathy (CIDP) mimic. Breast Cancer Research and Treatment, 220(1). https://doi.org/10.1007/s10549-026-08081-6

Vancouver

Zeynoun J, Evans M, Boldig K, Ali H. A rare neurological adverse event of palbociclib: a chronic inflammatory demyelinating polyneuropathy (CIDP) mimic. Breast Cancer Research and Treatment. 2026;220(1). doi:10.1007/s10549-026-08081-6

BibTeX
@article{Zeynoun2026,
  author = {Zeynoun, Joy and Evans, Madeline and Boldig, Kimberly and Ali, Haythem},
  title = {A rare neurological adverse event of palbociclib: a chronic inflammatory demyelinating polyneuropathy (CIDP) mimic},
  journal = {Breast Cancer Research and Treatment},
  year = {2026},
  volume = {220},
  number = {1},
  doi = {10.1007/s10549-026-08081-6}
}
Kostenlos starten →